113 related articles for article (PubMed ID: 37394063)
1. PhosphoDisco: A Toolkit for Co-regulated Phosphorylation Module Discovery in Phosphoproteomic Data.
Schraink T; Blumenberg L; Hussey G; George S; Miller B; Mathew N; González-Robles TJ; Sviderskiy V; Papagiannakopoulos T; Possemato R; Fenyö D; Ruggles KV
Mol Cell Proteomics; 2023 Aug; 22(8):100596. PubMed ID: 37394063
[TBL] [Abstract][Full Text] [Related]
2. Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors.
Schweppe DK; Rigas JR; Gerber SA
J Proteomics; 2013 Oct; 91():286-96. PubMed ID: 23911959
[TBL] [Abstract][Full Text] [Related]
3. Bayesian analysis of dynamic phosphoproteomic data identifies protein kinases mediating GPCR responses.
Leo KT; Chou CL; Yang CR; Park E; Raghuram V; Knepper MA
Cell Commun Signal; 2022 Jun; 20(1):80. PubMed ID: 35659261
[TBL] [Abstract][Full Text] [Related]
4. Inference of kinase-signaling networks in human myeloid cell line models by Phosphoproteomics using kinase activity enrichment analysis (KAEA).
Hallal M; Braga-Lagache S; Jankovic J; Simillion C; Bruggmann R; Uldry AC; Allam R; Heller M; Bonadies N
BMC Cancer; 2021 Jul; 21(1):789. PubMed ID: 34238254
[TBL] [Abstract][Full Text] [Related]
5. Phosphoproteomics identifies oncogenic Ras signaling targets and their involvement in lung adenocarcinomas.
Sudhir PR; Hsu CL; Wang MJ; Wang YT; Chen YJ; Sung TY; Hsu WL; Yang UC; Chen JY
PLoS One; 2011; 6(5):e20199. PubMed ID: 21637843
[TBL] [Abstract][Full Text] [Related]
6. Phosphoproteomics Profiling to Identify Altered Signaling Pathways and Kinase-Targeted Cancer Therapies.
Deb B; George IA; Sharma J; Kumar P
Methods Mol Biol; 2020; 2051():241-264. PubMed ID: 31552632
[TBL] [Abstract][Full Text] [Related]
7. Quantitative phosphoproteomics studies using stable isotope dimethyl labeling coupled with IMAC-HILIC-nanoLC-MS/MS for estrogen-induced transcriptional regulation.
Wu CJ; Chen YW; Tai JH; Chen SH
J Proteome Res; 2011 Mar; 10(3):1088-97. PubMed ID: 21210654
[TBL] [Abstract][Full Text] [Related]
8. Co-expression module analysis reveals biological processes, genomic gain, and regulatory mechanisms associated with breast cancer progression.
Shi Z; Derow CK; Zhang B
BMC Syst Biol; 2010 May; 4():74. PubMed ID: 20507583
[TBL] [Abstract][Full Text] [Related]
9. Integrating proteomic and phosphoproteomic data for pathway analysis in breast cancer.
Ren J; Wang B; Li J
BMC Syst Biol; 2018 Dec; 12(Suppl 8):130. PubMed ID: 30577793
[TBL] [Abstract][Full Text] [Related]
10. Identifying novel targets of oncogenic EGF receptor signaling in lung cancer through global phosphoproteomics.
Zhang X; Belkina N; Jacob HK; Maity T; Biswas R; Venugopalan A; Shaw PG; Kim MS; Chaerkady R; Pandey A; Guha U
Proteomics; 2015 Jan; 15(2-3):340-55. PubMed ID: 25404012
[TBL] [Abstract][Full Text] [Related]
11. Identification and validation of new ERK substrates by phosphoproteomic technologies including Phos-tag SDS-PAGE.
Yoshikawa H; Nishino K; Kosako H
J Proteomics; 2022 Apr; 258():104543. PubMed ID: 35231659
[TBL] [Abstract][Full Text] [Related]
12. Study of the co-expression gene modules of non-small cell lung cancer metastases.
Wang G; Bie F; Li G; Shi J; Zeng Y; Du J
Cancer Biomark; 2021; 30(3):321-329. PubMed ID: 33337349
[TBL] [Abstract][Full Text] [Related]
13. Identification of potential therapeutic target genes and mechanisms in non-small-cell lung carcinoma in non-smoking women based on bioinformatics analysis.
Zhou W; Yin M; Cui H; Wang N; Zhao LL; Yuan LZ; Yang XP; Ding XM; Men FZ; Ma X; Na JR
Eur Rev Med Pharmacol Sci; 2015 Sep; 19(18):3375-84. PubMed ID: 26439031
[TBL] [Abstract][Full Text] [Related]
14. A map of the phosphoproteomic alterations that occur after a bout of maximal-intensity contractions.
Potts GK; McNally RM; Blanco R; You JS; Hebert AS; Westphall MS; Coon JJ; Hornberger TA
J Physiol; 2017 Aug; 595(15):5209-5226. PubMed ID: 28542873
[TBL] [Abstract][Full Text] [Related]
15. Phosphoproteomics Profiling of Nonsmall Cell Lung Cancer Cells Treated with a Novel Phosphatase Activator.
Wiredja DD; Ayati M; Mazhar S; Sangodkar J; Maxwell S; Schlatzer D; Narla G; Koyutürk M; Chance MR
Proteomics; 2017 Nov; 17(22):. PubMed ID: 28961369
[TBL] [Abstract][Full Text] [Related]
16. PhosR enables processing and functional analysis of phosphoproteomic data.
Kim HJ; Kim T; Hoffman NJ; Xiao D; James DE; Humphrey SJ; Yang P
Cell Rep; 2021 Feb; 34(8):108771. PubMed ID: 33626354
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy Snapshots of Key Phosphoproteomic Pathways in Lung Cancer Patients for Diagnosis and Therapy Monitoring.
Ahmed M; Wuethrich A; Constantin N; Shanmugasundaram KB; Mainwaring P; Kulasinghe A; O'Leary C; O'Byrne K; Sina AA; Carrascosa LG; Trau M
Anal Chem; 2023 Jun; 95(22):8522-8532. PubMed ID: 37224231
[TBL] [Abstract][Full Text] [Related]
18. Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity.
Wolf DM; Lenburg ME; Yau C; Boudreau A; van 't Veer LJ
PLoS One; 2014; 9(2):e88309. PubMed ID: 24516633
[TBL] [Abstract][Full Text] [Related]
19. Phosphoproteomic Identification of Vasopressin/cAMP/Protein Kinase A-Dependent Signaling in Kidney.
Salhadar K; Matthews A; Raghuram V; Limbutara K; Yang CR; Datta A; Chou CL; Knepper MA
Mol Pharmacol; 2021 May; 99(5):358-369. PubMed ID: 32245905
[TBL] [Abstract][Full Text] [Related]
20. Phosphosignature predicts dasatinib response in non-small cell lung cancer.
Klammer M; Kaminski M; Zedler A; Oppermann F; Blencke S; Marx S; Müller S; Tebbe A; Godl K; Schaab C
Mol Cell Proteomics; 2012 Sep; 11(9):651-68. PubMed ID: 22617229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
